Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/591797


Czech Republic Pharmaceuticals & Healthcare Report Q1 2008


Description: The Czech Republic Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on the Czech Republics pharmaceuticals and healthcare industry.

The drug market in the Czech Republic is showing promise, although local generics producers may struggle to cash in, in the short-term. BMI forecasts a compound growth rate (CAGR) of 6.84% for 2007- 2012. However, recent reforms have targeted older generic drugs, as the authorities attempts to constrain costs. Leading local producer Zentiva recorded a disappointing performance in the Czech Republic in H107, with sales receding 5.6% to CZK2,226mn (US$115.08mn), although BMI remains bullish about the firms prospects in the medium to long term.

Meanwhile, after much political machination, the government has managed to push through its reform agenda, which includes a programme of tax cuts aimed at slashing the country’s large fiscal burden. Reforms include the adoption of a flat-rate system for both income and corporate tax, which will eventually stand at 15% and 19% respectively. At the same time, value-added tax (VAT) will be raised to 9% from 5%. With regards to the countrys welfare system, reductions in child benefits and parental contributions will be introduced, as well as patient fees for doctor visits and hospital stays. BMI expects health expenditure to reach US$19bn by 2012, or equivalent to 8% of GDP. Although low by Western European standards, it is quite high compared with its immediate neighbours. The fiscally conservative administration is also likely to usher in a significant shift away from state health expenditure in favour of private providers.

The Czech Republic comes in second place in our revamped Business Environment Rankings. Its position is mainly due to the strength of the drug market, with per-capita spending forecast to reach US$305.4 for 2007. Patent protection, however, is a long-standing problem in the Czech Republic, due to the industry policy under the previous Communist government, which did not recognise patents on many end-products and local production of copies of Western medicines. The countrys EU membership and the adoption of pharmaceutical directives have at least in theory eased many problems related to drug copying.


Contents: Executive Summary
Czech Republic Pharmaceuticals and Healthcare Industry SWOT
Czech Republic Political SWOT
Czech Republic Economic SWOT
Czech Republic Business Environment SWOT
Pharmaceutical Business Environment Ratings
Pharmaceutical Ratings - Revised Methodology
Ratings Overview

Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Czech Republic - Pharmaceutical Business Environment Rat
Table: Central and Eastern Europe Pharmaceutical Business Environment Ratings
Limits to Potential Returns
Risks to Realisation of Returns
Central and Eastern Europe Overview

Czech Republic - Market Summary
Regulatory Regime
Intellectual Property Environment
Pricing and Reimbursement Issues
Pharmacy Sector
Hospital Sector
Healthcare Sector
Research and Development Sector
Industry Forecast Scenario

Overall Market Forecast
Table: Czech Republic’s Drug Market Forecast Indicators, 2005-2011
Key Growth Factors - Industry
Table: Czech Republic’s Health Expenditure Forecast Indicators
Key Growth Factors - Macroeconomic
Table: Czech Republic - Economic Activity
Prescription And OTC Market Forecasts
Table: Czech Republic’s Prescription Drug Market Indicators (US$mn unless otherwise stated)
Table: OTC Drugs Market Forecast Indicators (US$mn unless otherwise stated)
Generics and Patented Market Forecasts
Table: Czech Republic’s Generics And Branded Market Forecast Indicators
Export/Import Forecasts
Table: Czech Republic Trade Indicators (US$mn)
Other Healthcare Data Forecasts
Table: Socio-Demographic Indicators
Key Risks To our Forecast Scenario
Competitive Landscape
Wholesale
Czech Republic Pharmaceuticals & Healthcare Report Q1 2008
Retail
Table: Pharmacies And Pharmacy Market Ratios

Company Monitor
AstraZeneca
Bristol-Myers Squibb
Sanofi-Aventis
Walmark
Zentiva (incorporating Sicomed)

BMI Forecast Modelling
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Sources


Companies Mentioned - AstraZeneca - Bristol-Myers Squibb - Sanofi-Aventis - Walmark - Zentiva (incorporating Sicomed)


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/591797

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 28/11/2009 20:33:23
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Czech Republic Pharmaceuticals & Healthcare Report Q1 2008
Web Address:
http://www.researchandmarkets.com/reports/591797
Office Code:
OC8HJNPOUMUXU

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €440.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 28/11/2009 20:33:23

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)